Bellicum Pharmaceutivals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The company develops chemical induction of dimerization technology platform to engineer and control components of the immune system. Bellicum Pharmaceutivals was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.
